Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SNDX Syndax Pharmaceuticals, Inc.

交易中 12-15 09:51:18 EST

20.87

+0.50

+2.45%

最高20.93	最低20.36	成交量9.25万
今开20.36	昨收20.37	日振幅2.80%
总市值18.14亿	流通市值15.18亿	总股本8,691万
成交额192.09万	换手率0.13%	流通股本7,272万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals, Inc. ","latestPrice":20.87,"timestamp":1765810275604,"preClose":20.37,"halted":0,"volume":92483,"delay":0,"floatShares":72721425,"shares":86914838,"eps":-3.600392,"marketStatus":"交易中","change":0.5,"latestTime":"12-15 09:51:18 EST","open":20.36,"high":20.93,"low":20.36,"amount":1920934.4285080002,"amplitude":0.027982,"askPrice":20.89,"askSize":481,"bidPrice":20.85,"bidSize":105,"shortable":3,"etf":0,"ttmEps":-3.600392,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765832400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1456981200000,"exchange":"NASDAQ","adjPreClose":20.37,"preHourTrading":{"tag":"盘前","latestPrice":20.48,"preClose":20.37,"latestTime":"09:29 EST","volume":2282,"amount":46690.505008,"timestamp":1765808999999},"postHourTrading":{"tag":"盘后","latestPrice":20.3,"preClose":20.37,"latestTime":"19:35 EST","volume":139462,"amount":2840713.265,"timestamp":1765586106156},"volumeRatio":0.834402,"impliedVol":0.1969,"impliedVolPercentile":0.044},"requestUrl":"/m/hq/s/SNDX","defaultTab":"news","newsList":[{"id":"2589272354","title":"Syndax公布AML联合疗法强劲数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2589272354","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589272354?lang=zh_cn&edition=full","pubTime":"2025-12-08 23:42","pubTimestamp":1765208520,"startTime":"0","endTime":"0","summary":"美股周一早盘，临床阶段的生物制药公司Syndax（SNDX）股价下跌3.2%。该公司在2025年美国血液学会（ASH）年会上展示了revumenib联合疗法的最新数据，在新诊断和移植后急性髓系白血病患者队列中显示出高缓解率和高微小残留病阴性率。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-08/doc-inhachkx2122015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4109","SNDX","LU2463526074.USD","BK4139","ASH"],"gpt_icon":0},{"id":"2585198332","title":"Syndax Pharmaceuticals, Inc.盘中异动 大幅拉升5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585198332","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585198332?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:50","pubTimestamp":1763650225,"startTime":"0","endTime":"0","summary":"北京时间2025年11月20日22时50分，Syndax Pharmaceuticals, Inc.股票出现波动，股价快速拉升5.15%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.51%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511202250259775c9ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511202250259775c9ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2579926172","title":"Syndax Pharmaceuticals, Inc.盘中异动 快速拉升5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579926172","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579926172?lang=zh_cn&edition=full","pubTime":"2025-10-29 00:48","pubTimestamp":1761670128,"startTime":"0","endTime":"0","summary":"北京时间2025年10月29日00时48分，Syndax Pharmaceuticals, Inc.股票出现异动，股价大幅拉升5.03%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.29%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029004848974708f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029004848974708f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"1143402682","title":"FDA 批准 Revumenib 治疗带有易感 Npm1 突变的复发或难治性急性髓性白血病","url":"https://stock-news.laohu8.com/highlight/detail?id=1143402682","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143402682?lang=zh_cn&edition=full","pubTime":"2025-10-25 01:15","pubTimestamp":1761326113,"startTime":"0","endTime":"0","summary":"FDA 批准 Revumenib 治疗带有易感 Npm1 突变的复发或难治性急性髓性白血病","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"1172232207","title":"Syndax Pharmaceuticals 股价在盘前上涨2.4%，因H.C. Wainwright 開始给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1172232207","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172232207?lang=zh_cn&edition=full","pubTime":"2025-10-16 18:15","pubTimestamp":1760609710,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals 股价在盘前上涨2.4%，因H.C. Wainwright 开始给予买入评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2565051642","title":"Syndax Pharmaceuticals, Inc.盘中异动 临近午盘急速上涨5.00%报17.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2565051642","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565051642?lang=zh_cn&edition=full","pubTime":"2025-09-05 23:40","pubTimestamp":1757086819,"startTime":"0","endTime":"0","summary":"北京时间2025年09月05日23时40分，Syndax Pharmaceuticals, Inc.股票出现异动，股价快速上涨5.00%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.02%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。消息层面，截至23时40分，《高盛集团维持Syndax Pharmaceuticals买入评级，上调目标价至24美元》资讯为影响Syndax Pharmaceuticals, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250905234020a4b69f70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250905234020a4b69f70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DX","SNDX","BK4139","BK4110"],"gpt_icon":0},{"id":"2558502128","title":"Syndax Pharmaceuticals, Inc.2025财年第二财季实现净利润-71.85百万美元，同比减少5.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558502128","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558502128?lang=zh_cn&edition=full","pubTime":"2025-08-10 00:01","pubTimestamp":1754755300,"startTime":"0","endTime":"0","summary":"8月10日，Syndax Pharmaceuticals, Inc.公布财报，公告显示公司2025财年第二财季净利润为-71.85百万美元，同比减少5.57%；其中营业收入为37.96百万美元，同比增加984.57%，每股基本收益为-0.83美元。机构评级：截至2025年8月10日，当前有11家机构对Syndax Pharmaceuticals, Inc.目标价做出预测，其中目标均价为36.36美元，其中最低目标价为19.00美元，最高目标价为56.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810000351a6dcb884&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810000351a6dcb884&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX"],"gpt_icon":0},{"id":"2557528308","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557528308","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557528308?lang=zh_cn&edition=full","pubTime":"2025-08-06 21:52","pubTimestamp":1754488337,"startTime":"0","endTime":"0","summary":"北京时间2025年08月06日21时52分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.25%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.32%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806215217973790bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806215217973790bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2557664397","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨20.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557664397","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557664397?lang=zh_cn&edition=full","pubTime":"2025-08-05 21:31","pubTimestamp":1754400699,"startTime":"0","endTime":"0","summary":"北京时间2025年08月05日21时31分，Syndax Pharmaceuticals, Inc.股票出现波动，股价大幅拉升20.40%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为2.54%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805213139a6d49d63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805213139a6d49d63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"1151605359","title":"异动解读 | 业绩超预期，Syndax Pharmaceuticals盘前大涨11.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151605359","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151605359?lang=zh_cn&edition=full","pubTime":"2025-08-05 16:10","pubTimestamp":1754381438,"startTime":"0","endTime":"0","summary":"生物制药公司Syndax Pharmaceuticals今日盘前股价大涨11.75%，引发市场广泛关注。根据Syndax Pharmaceuticals公布的财报，公司第二季度调整后每股亏损为0.83美元，优于分析师平均预期的1.02美元亏损。这一乐观预期进一步推动了投资者的积极情绪，促使Syndax Pharmaceuticals股价在盘前交易中大幅上涨。随着市场对公司业绩和发展前景的信心增强，Syndax Pharmaceuticals的股价走势值得投资者持续关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SNDX"],"gpt_icon":0},{"id":"1152687569","title":"异动解读 | 业绩超预期，Syndax Pharmaceuticals夜盘大涨11.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152687569","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152687569?lang=zh_cn&edition=full","pubTime":"2025-08-05 08:42","pubTimestamp":1754354570,"startTime":"0","endTime":"0","summary":"生物制药公司Syndax Pharmaceuticals在发布第二季度财报后，股价在夜盘交易中大涨11.66%，引起投资者广泛关注。根据公司公布的财报，Syndax Pharmaceuticals第二季度调整后每股亏损0.83美元，优于分析师预期的1.02美元亏损。这一亮眼的业绩表现成为推动股价大涨的主要原因。值得注意的是，尽管公司仍处于亏损状态，但其营收的显著增长表明公司业务正在快速发展。这些因素共同推动了投资者的乐观情绪，促使Syndax Pharmaceuticals股价在夜盘交易中大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SNDX"],"gpt_icon":0},{"id":"1199110403","title":"异动解读 | 盈利报告前夕，Syndax Pharmaceuticals盘前大涨5.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199110403","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199110403?lang=zh_cn&edition=full","pubTime":"2025-08-04 20:04","pubTimestamp":1754309070,"startTime":"0","endTime":"0","summary":"周一盘前交易中，生物制药公司Syndax Pharmaceuticals股价大幅上涨5.91%，引发市场关注。这一显著涨幅出现在该公司计划发布第二季度财报之际。根据最新公布的财报日程，Syndax Pharmaceuticals将于本交易日收盘后公布其2025年第二季度财务业绩。投资者似乎对即将公布的业绩报告持乐观态度，推动了股价的上涨。因此，市场可能预期Syndax在财报中将公布一些积极的业务进展。然而，在正式财报公布之前，投资者仍需保持谨慎，密切关注公司的官方公告。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SNDX"],"gpt_icon":0},{"id":"2555057783","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘大幅上涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555057783","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555057783?lang=zh_cn&edition=full","pubTime":"2025-07-29 22:51","pubTimestamp":1753800674,"startTime":"0","endTime":"0","summary":"北京时间2025年07月29日22时51分，Syndax Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.12%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729225114a6c80fe8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729225114a6c80fe8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2552439463","title":"Syndax Pharmaceuticals, Inc.盘中异动 下午盘快速上涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552439463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552439463?lang=zh_cn&edition=full","pubTime":"2025-07-18 03:12","pubTimestamp":1752779544,"startTime":"0","endTime":"0","summary":"北京时间2025年07月18日03时12分，Syndax Pharmaceuticals, Inc.股票出现波动，股价快速上涨5.08%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.27%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718031224a6b05f0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718031224a6b05f0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2551193315","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551193315","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551193315?lang=zh_cn&edition=full","pubTime":"2025-07-15 22:37","pubTimestamp":1752590228,"startTime":"0","endTime":"0","summary":"北京时间2025年07月15日22时37分，Syndax Pharmaceuticals, Inc.股票出现波动，股价大幅下挫5.03%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.16%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715223708a6ab701c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715223708a6ab701c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2550624591","title":"Syndax Pharmaceuticals, Inc.盘中异动 大幅拉升5.19%报9.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550624591","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550624591?lang=zh_cn&edition=full","pubTime":"2025-07-10 23:11","pubTimestamp":1752160294,"startTime":"0","endTime":"0","summary":"北京时间2025年07月10日23时11分，Syndax Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.19%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.94%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710231135a6a1e5a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710231135a6a1e5a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2550465347","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.26%报9.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550465347","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550465347?lang=zh_cn&edition=full","pubTime":"2025-07-09 21:49","pubTimestamp":1752068944,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日21时49分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.26%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.97%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709214904a69f9381&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709214904a69f9381&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2548818722","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548818722","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548818722?lang=zh_cn&edition=full","pubTime":"2025-07-02 22:12","pubTimestamp":1751465539,"startTime":"0","endTime":"0","summary":"北京时间2025年07月02日22时12分，Syndax Pharmaceuticals, Inc.股票出现波动，股价快速上涨5.12%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.84%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702221219a4cb6328&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702221219a4cb6328&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2548017512","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.09%报9.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548017512","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548017512?lang=zh_cn&edition=full","pubTime":"2025-07-01 03:37","pubTimestamp":1751312257,"startTime":"0","endTime":"0","summary":"北京时间2025年07月01日03时37分，Syndax Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.09%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.30%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070103373795319a43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070103373795319a43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2546324177","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.00%报9.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546324177","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546324177?lang=zh_cn&edition=full","pubTime":"2025-06-26 22:45","pubTimestamp":1750949154,"startTime":"0","endTime":"0","summary":"北京时间2025年06月26日22时45分，Syndax Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.00%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626224554a4bf61a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626224554a4bf61a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":0.0025},{"period":"1month","weight":0.2132},{"period":"3month","weight":0.31},{"period":"6month","weight":0.9873},{"period":"1year","weight":0.5122},{"period":"ytd","weight":0.5408}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Syndax Pharmaceuticals, Inc.于2005年10月11日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，正在开发癌症疗法的创新管道。该公司正在开发revumenib，这是一种有效的、选择性的、menin-MLL结合相互作用的小分子抑制剂，用于治疗KMT2A重排或KMT2AR，也称为混合谱系白血病重排或MLLR，包括急性淋巴细胞白血病或ALL在内的急性白血病，以及急性髓细胞白血病或AML，以及necleophosmin 1，也称为NPM1，突变AML。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.047367},{"month":2,"riseRate":0.666667,"avgChangeRate":0.081651},{"month":3,"riseRate":0.555556,"avgChangeRate":0.051247},{"month":4,"riseRate":0.4,"avgChangeRate":0.014629},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019495},{"month":6,"riseRate":0.5,"avgChangeRate":-0.003538},{"month":7,"riseRate":0.6,"avgChangeRate":0.016261},{"month":8,"riseRate":0.6,"avgChangeRate":0.106119},{"month":9,"riseRate":0.5,"avgChangeRate":-0.031411},{"month":10,"riseRate":0.2,"avgChangeRate":-0.077781},{"month":11,"riseRate":0.6,"avgChangeRate":0.04592},{"month":12,"riseRate":0.5,"avgChangeRate":0.032709}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals, Inc. ","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Syndax Pharmaceuticals, Inc. ,SNDX,Syndax Pharmaceuticals, Inc. 股票,Syndax Pharmaceuticals, Inc. 股票老虎,Syndax Pharmaceuticals, Inc. 股票老虎国际,Syndax Pharmaceuticals, Inc. 行情,Syndax Pharmaceuticals, Inc. 股票行情,Syndax Pharmaceuticals, Inc. 股价,Syndax Pharmaceuticals, Inc. 股市,Syndax Pharmaceuticals, Inc. 股票价格,Syndax Pharmaceuticals, Inc. 股票交易,Syndax Pharmaceuticals, Inc. 股票购买,Syndax Pharmaceuticals, Inc. 股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}